Dongwha Pharm.Co.,Ltd (KRX:000020)
South Korea
· Delayed Price · Currency is KRW 6,130.00
-30.00 (-0.49%)
At close: Mar 26, 2025, 3:30 PM KST
Dongwha Pharm.Co.,Ltd Revenue
In the year 2024, Dongwha Pharm.Co.,Ltd had annual revenue of 464.87B KRW with 28.74% growth. Dongwha Pharm.Co.,Ltd had revenue of 120.63B in the quarter ending December 31, 2024, with 43.20% growth.
Revenue
464.87B
Revenue Growth
+28.74%
P/S Ratio
0.36
Revenue / Employee
569.70M
Employees
816
Market Cap
167.97B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 464.87B | 103.77B | 28.74% |
| Dec 31, 2023 | 361.11B | 20.68B | 6.08% |
| Dec 31, 2022 | 340.43B | 47.41B | 16.18% |
| Dec 31, 2021 | 293.02B | 20.94B | 7.70% |
| Dec 31, 2020 | 272.08B | -35.07B | -11.42% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2012 | Pro | Pro | Pro |
| Dec 31, 2011 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 4,547.32B |
| Celltrion | 3,557.30B |
| ALTEOGEN | 102.85B |
| Yuhan | 2,067.79B |
| SK Biopharmaceuticals | 547.60B |
| HLB Co., Ltd. | 51.92B |
| Sam Chun Dang Pharm. | 210.92B |
| PharmaResearch | 350.12B |